<DOC>
	<DOCNO>NCT01678105</DOCNO>
	<brief_summary>This non-randomized , phase II , open label study dovitinib patient progressive , recurrent and/or metastatic adenoid cystic carcinoma ( ACC ) . The primary purpose study ass anti-cancer effect dovitinib population order evaluate whether dovitinib worthy study patient progressive ACC .</brief_summary>
	<brief_title>A Phase II Study Dovitinib Recurrent and/or Metastatic Adenoid Cystic Carcinoma Salivary Glands</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Salivary Gland Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Adenoid Cystic</mesh_term>
	<criteria>Histologically cytologically confirm ACC major minor salivary gland . Recurrent and/or metastatic disease deem progressive amenable surgery curative radiotherapy . Measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST , version 1.1 ) , define least one lesion accurately measure least one dimension ( long diameter plane measurement record ) minimum size : &gt; 10 mm CT scan ( CT scan slice thickness great 5 mm ) . &gt; 10 mm caliper measurement clinical exam ( lesion accurately measure caliper record nonmeasurable ) . &gt; 20 mm chest Xray Malignant lymph node : To consider pathologically enlarge measurable , lymph node must &gt; 15mm short axis assess CT scan ( CT scan slice thickness recommend great 5 mm ) . Progressive disease , define one follow occur within 12 month study entry : ) least 10 % increase radiologically clinically measurable disease ; ii ) appearance one new lesion , iii ) deterioration clinical status . Less 18 year age . Life expectancy &lt; 12 week . ECOG performance status &gt; 2 . Known brain metastasis . Treatment chemotherapy radiotherapy within 4 week ( 6 week nitrosoureas mitomycin C ) prior enter study recover adverse event due agent administer 4 week earlier . Major surgery within 4 week prior enter study . History allergic reaction attribute compound similar chemical biologic composition dovitinib . Taking medication potent CYP3A4 inducer inhibitor ( dovitinib metabolize primarily CYP3A4 liver enzyme , every effort make switch patient take agent substance medication ) . History cardiac dysfunction ECHO MUGA scan outside institutional range normal . QTc prolongation ( define QTc interval &gt; 500 msec ) significant ECG abnormality . Poorly control hypertension ( systolic blood pressure ≥ 140 mmHg diastolic blood pressure ≥ 90 mmHg ) . Any abnormal organ marrow function define : Leukocytes &lt; 3,000/microL Absolute neutrophil count &lt; 1,500/microL Platelets &lt; 100,000/microL Total bilirubin &gt; 1.5X institutional upper limit normal ( ULN ) AST ( SGOT ) / ALT ( SGPT ) &gt; 2.5X institutional ULN Amylase/lipase outside normal institutional limit Serum creatinine &gt; 1.5X ULN Creatinine clearance &lt; 60mL/min/1.73 m2 patient creatinine level institutional normal Required use therapeutic dos coumarinderivative anticoagulant warfarin , although dos 2mg daily permit prophylaxis thrombosis . Note : Low molecular weight heparin permit provided patient 's PT INR ≤ 1.5 . Preexisting condition ( e.g. , gastrointestinal tract disease ) , result inability take oral medication requirement IV alimentation , prior surgical procedure affect absorption , active peptic ulcer disease impair ability swallow retain dovitinib tablet . Preexisting thyroid abnormality inability maintain thyroid function normal range medication . Any following condition : Serious nonhealing wound , ulcer , bone fracture , History abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 28 day treatment , History cerebrovascular accident ( CVA ) transient ischemic attack ( TIA ) within 12 month prior study entry , History pulmonary embolism within past 12 month , History myocardial infarction , cardiac arrhythmia , stable/unstable angina , symptomatic congestive heart failure , coronary/peripheral artery bypass graft stenting within 12 month prior study entry , NYHA Class III IV heart failure define NYHA functional classification system . Uncontrolled intercurrent illness include , limited , ongoing active infection , HIVpositive patient combination antiretroviral therapy . Pregnant lactating woman . Psychiatric illness/social situation would limit compliance study requirement . Receiving investigational agent ( ) . Inability understand unable provide write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Recurrent Adenoid Cystic Carcinoma Salivary Glands</keyword>
	<keyword>Metastatic Adenoid Cystic Carcinoma Salivary Glands</keyword>
	<keyword>Salivary Gland Cancers</keyword>
	<keyword>ACC</keyword>
	<keyword>Dovitinib</keyword>
	<keyword>TKI258</keyword>
	<keyword>RTK Inhibitor</keyword>
</DOC>